Mr. Reali resigned April 4, and Anthony Bihl was appointed interim CEO, according to an April 3 SEC filing from Bioventus. Mr. Bihl has more than 35 years of experience in the medtech industry, according to an April 5 company news release.
Bioventus is currently seeking a permanent CEO. Mr. Reali’s departure comes just over a month after the company said its $450 million acquisition of CartiHeal may not happen.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
